ReShape Lifesciences Inc (RSLS) - Total Assets
Based on the latest financial reports, ReShape Lifesciences Inc (RSLS) holds total assets worth $9.03 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ReShape Lifesciences Inc balance sheet quality to measure how much of total assets are equity-financed.
ReShape Lifesciences Inc - Total Assets Trend (2003–2024)
This chart illustrates how ReShape Lifesciences Inc's total assets have evolved over time, based on quarterly financial data. Check RSLS cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
ReShape Lifesciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
ReShape Lifesciences Inc's total assets of $9.03 Million consist of 95.7% current assets and 4.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.5% |
| Accounts Receivable | $987.00K | 20.6% |
| Inventory | $2.46 Million | 51.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2003–2024)
This chart illustrates how ReShape Lifesciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ReShape Lifesciences Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ReShape Lifesciences Inc's current assets represent 95.7% of total assets in 2024, an increase from 0.0% in 2003.
- Cash Position: Cash and equivalents constituted 14.5% of total assets in 2024, up from 0.0% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2003.
- Asset Diversification: The largest asset category is inventory at 51.3% of total assets.
ReShape Lifesciences Inc Competitors by Total Assets
Key competitors of ReShape Lifesciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥912.83 Million |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$123.37 Million |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Dirui Industrial Co Ltd
SHE:300396
|
China | CN¥2.62 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
ReShape Lifesciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.77 | 1.90 | 0.57 |
| Quick Ratio | 1.97 | 0.89 | 0.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.66 Million | $2.89 Million | $-6.12 Million |
ReShape Lifesciences Inc - Advanced Valuation Insights
This section examines the relationship between ReShape Lifesciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 30.42 |
| Latest Market Cap to Assets Ratio | 1.95 |
| Asset Growth Rate (YoY) | -55.1% |
| Total Assets | $4.79 Million |
| Market Capitalization | $9.35 Million USD |
Valuation Analysis
Above Book Valuation: The market values ReShape Lifesciences Inc's assets above their book value (1.95x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: ReShape Lifesciences Inc's assets decreased by 55.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ReShape Lifesciences Inc (2003–2024)
The table below shows the annual total assets of ReShape Lifesciences Inc from 2003 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $4.79 Million | -55.05% |
| 2023-12-31 | $10.66 Million | -4.30% |
| 2022-12-31 | $11.14 Million | -79.46% |
| 2021-12-31 | $54.26 Million | +46.40% |
| 2020-12-31 | $37.06 Million | -6.54% |
| 2019-12-31 | $39.66 Million | -14.30% |
| 2018-12-31 | $46.27 Million | -47.84% |
| 2017-12-31 | $88.70 Million | +1159.84% |
| 2016-12-31 | $7.04 Million | -39.23% |
| 2015-12-31 | $11.59 Million | -19.46% |
| 2014-12-31 | $14.39 Million | -45.48% |
| 2013-12-31 | $26.39 Million | +1.12% |
| 2012-12-31 | $26.10 Million | -19.67% |
| 2011-12-31 | $32.49 Million | -16.03% |
| 2010-12-31 | $38.69 Million | +138.60% |
| 2009-12-31 | $16.21 Million | -42.66% |
| 2008-12-31 | $28.28 Million | -52.11% |
| 2007-12-31 | $59.05 Million | +63.74% |
| 2006-12-31 | $36.06 Million | +211.95% |
| 2005-12-31 | $11.56 Million | +1512.39% |
| 2003-12-31 | $717.00K | -- |
About ReShape Lifesciences Inc
As of August 14, 2025, ReShape Lifesciences Inc. was acquired by Vyome Therapeutics Inc., in a reverse merger transaction. ReShape Lifesciences Inc. provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System to treat obesity and invasive surgical stapling… Read more